Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks, as is the standard
administration dose and schedule. This application is a non-labeled indication for
cabazitaxel and will inform future drug development in gastroesophageal malignancies, where
docetaxel remains an approved first line agent, but is not routinely used due to excessive
toxicity and marginal efficacy.
At the conclusion of this study, we hope to demonstrate activity of single agent cabazitaxel
in refractory gastric cancer, with preferential activity in one or more gastric cancer
subtypes